Circulating melanoma cells and survival in metastatic melanoma
Circulating melanoma cells and survival in metastatic melanoma
复制标题
DOI：
10.3892/ijo.2011.896
复制
发表时间：
2011-03-01
影响因子：
5.2
通讯作者：
Terstappen, L. W. M. M.
中科院分区：
文献类型：
--
作者：
Rao, C.;Bui, T.;Terstappen, L. W. M. M.
一种经过验证的循环黑色素瘤细胞 (CMC) 计数分析方法可能有助于为转移性黑色素瘤患者开发更有效的疗法。在这项研究中，CD146(+) 细胞从 7.5 ml 血液中进行免疫磁性富集。分离的细胞用抗分子量黑色素瘤相关抗原 (HMW-MAA) DAPI 进行荧光染色。抗CD45、CD34和Ki67。 CMCs被鉴定为CD146(+)、HMW-MAA(+)、CD45(-)、CD34(-)、Ki67(-/+)细胞。 7.5 ml 血液中 88% 的加标 SK-MEL28 细胞被回收。在所有 55 名健康捐献者中，每 7.5 毫升全血中有 2 个 CMC，与少于 2 个 CMC 的组相比，总生存期较短（2.0 个月 vs. 12.1 个月，P=0.001）。
A validated assay for the enumeration of circulating melanoma cells (CMCs) may facilitate the development of more effective therapies for metastatic melanoma patients. In this study CD146(+) cells were immunomagnetically enriched from 7.5 ml of blood. Isolated cells were fluorescently stained with DAPI, anti-molecular weight melanoma-associated antigen (HMW-MAA). anti-CD45 and CD34 and Ki67. CMCs were identified as CD146(+), HMW-MAA(+), CD45(-), CD34(-), Ki67(-/+) cells. Eighty-eight percent of spiked SK-MEL28 cells in 7.5 ml blood were recovered. In all 55 healthy donors = 2 CMCs per 7.5 ml of whole blood, as compared with the group with < 2 CMCs, had a shorter overall survival (2.0 months vs. 12.1 months, P=0.001).